1) Miyagi M, Millecamps M, Danco AT, et al. ISSLS Prize winner:Increased innervation and sensory nervous system plasticity in a mouse model of low back pain due to intervertebral disc degeneration. Spine (Phila Pa 1976) 2014;39(17):1345-54. doi:10.1097/BRS.0000000000000334.
2) Ohtori S, Kinoshita T, Yamashita M, et al. Results of surgery for discogenic low back pain:a randomized study using discography versus discoblock for diagnosis. Spine (Phila Pa 1976) 2009;34(13):1345-8. doi:10.1097/BRS.0b013e3181a401bf.
3) Bobechko WP, Hirsch C. Auto-immune response to nucleus pulposus in the rabbit. J Bone Joint Surg Br 1965;47:574-80.
4) Haro H, Crawford HC, Fingleton B, et al. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 2020;105(2):143-50. doi:10.1172/jci7091.
5) Yepes M, Winkles JA. Inhibition of TWEAK activity as a new treatment for inflammatory and degenerative diseases. Drug News Perspect 2006;19(10):589-95. doi:10.1358/dnp.2006.19.10.1068005.
6) Perper SJ, Browning B, Burkly LC, et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006;177(4):2610-20.
7) Li H, Mittal A, Paul PK, et al. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase:a potential role of MMP-9 in myopathy. J Biolo Chem 2009;284(7):4439-50. doi:10.1074/jbc.M805546200.
8) Wako M, Haro H, Ando T, et al. Novel function of TWEAK in inducing intervertebral disc degeneration. J Orthop Res 2007;25(11):1438-46. doi:10.1002/jor.20445.
9) Wako M, Ohba T, Ando T, et al. Mechanism of signal transduction in tumor necrosis factor-like weak inducer of apoptosis-induced matrix degradation by MMP-3 upregulation in disc tissues. Spine (Phila Pa 1976) 2008;33(23):2489-94. doi:10.1097/BRS.0b013e318186b343.
10) Burkly LC, Michaelson JS, Hahm K, et al. TWEAKing tissue remodeling by a multifunctional cytokine:role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007;40(1):1-16. doi:10.1016/j.cyto.2007.09.007.
11) Zhou B, Comeau MR, De Smedt T, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol 2005;6(10):1047-53. doi:10.1038/ni1247.
12) Liu YJ. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol 2007;120(2):238-44. doi:10.1016/j.jaci.2007.06.004
13) Ohba T, Haro H, Ando T, et al. TNF-alpha-induced NF-kappaB signaling reverses age-related declines in VEGF induction and angiogenic activity in intervertebral disc tissues. J Orthop Res 2009;27(2):229-35. doi:10.1002/jor.20727
14) Raj PP. Intervertebral disc:anatomy-physiology-pathophysiology-treatment. Pain Pract 2008;8(1):18-44. doi:10.1111/j.1533-2500.2007.00171.x
15) Ohba T, Haro H, Ando T, et al. A potential role of thymic stromal lymphopoietin in the recruitment of macrophages to mouse intervertebral disc cells via monocyte chemotactic protein 1 induction:implications for herniated discs. Arthritis Rheum 2008;58(11):3510-9. doi:10.1002/art.23965.
16) Zhu Y, Ohba T, Ando T, et al. Endogenous TGF-β activity limits TSLP expression in the intervertebral disc tissue by suppressing NF-κB activation. J Orthop Res 2013;31(7):1144-9. doi:10.1002/jor.22337.
17) Ziegler SF, Artis D. Sensing the outside world:TSLP regulates barrier immunity. Nat Immunol 2010;11(4):289-93. doi:10.1038/ni.1852.
18) Ozawa T, Koyama K, Ando T, et al. Thymic stromal lymphopoietin secretion of synovial fibroblasts is positively and negatively regulated by Toll-like receptors/nuclear factor-kappaB pathway and interferon-gamma/dexamethasone. Mod Rheumatol 2007;17(6):459-63. doi:10.1007/s10165-007-0620-9.
19) Koyama K, Ohba T, Haro H, et al. Positive association between serum thymic stromal lymphopoietin and anti-citrullinated peptide antibodies in patients with rheumatoid arthritis. Clin Exp Immunol 2015;181(2):239-43. doi:10.1111/cei.12632.